Stock Events

Stock Events

Amniotics AB 

SEK0.01
1
+SEK0+5.88% Friday 15:29

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0.01
Dividend Yield
-
Dividend
-

Earnings

21MayExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q1 2024
-0.45
-0.38
-0.3
-0.22
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMNI.ST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited focuses on the development of regenerative medicine and cell therapies, similar to Amniotics' focus on stem cell-based therapies.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap6.74M
Brainstorm Cell Therapeutics works on stem cell-based therapies for neurodegenerative diseases, competing in the cell therapy space with Amniotics.
Vericel
VCEL
Mkt Cap1.77B
Vericel Corporation produces cell therapies for the treatment of patients with serious diseases and conditions, similar to Amniotics' approach in regenerative medicine.
Stem
STEM
Mkt Cap164.53M
StemCells, Inc. is involved in the research and development of cell-based therapeutics, directly competing with Amniotics in the stem cell innovation sector.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell media, crucial for companies like Amniotics in the cell therapy industry.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is engaged in the development of programmed cellular immunotherapies, sharing the cell therapy market space with Amniotics.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. focuses on the development of gene therapies that could be seen as alternative treatments to Amniotics' stem cell therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG works on gene editing, a technology that competes with stem cell therapy approaches like those pursued by Amniotics.

About

Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Show more...
CEO
Mr. Marcus Larsson Ph.D.
Employees
4
Country
Sweden

Listings

0 Comments

Share your thoughts

FAQ

What is Amniotics AB stock price today?▼
The current price of AMNI.ST is SEK0.01 SEK — it has increased by +5.88% in the past 24 hours. Watch Amniotics AB stock price performance more closely on the chart.
What is Amniotics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amniotics AB stocks are traded under the ticker AMNI.ST.
How many employees does Amniotics AB have?▼
As of April 02, 2026, the company has 4 employees.
In which sector is Amniotics AB located?▼
Amniotics AB operates in the Healthcare sector.
When did Amniotics AB complete a stock split?▼
Amniotics AB has not had any recent stock splits.
Where is Amniotics AB headquartered?▼
Amniotics AB is headquartered in Lund, Sweden.